LCM
PAVM icon

Lazari Capital Management’s PAVmed PAVM Stock Holding History

Lazari Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-198
Closed -$26.2K – 128
2023
Q3 		$26.2K Hold
198
– – 0.02% 117
2023
Q2 		$36.3K Buy
+198
New +$39.6K 0.02% 124

Other funds holding PAVM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
XF
XML Financial Bethesda, Maryland $1.24B AUM 20.4% 1-Year Est. Return

Lazari Capital Management's PAVM Position: Q4 2023 in Review

Lazari Capital Management sold out of PAVmed (PAVM) in Q4 2023, closing a stake of 198 shares — an estimated $26.2K sold.

Lazari Capital Management first reported a position in PAVM in Q2 2023 and held it in 2 quarters. The position peaked at $36.3K in Q2 2023. 23 funds tracked by Wall St. Rank hold PAVM as of Q4 2023.

  • Lazari Capital Management reported no remaining PAVmed position as of Q4 2023 after selling out during the quarter.
  • Lazari Capital Management sold 198 PAVmed shares in Q4 2023, an estimated $26.2K.
  • Lazari Capital Management first reported a position in PAVmed in Q2 2023 and held it in 2 quarters.
  • Lazari Capital Management's PAVmed position peaked at $36.3K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held PAVmed as of Q4 2023.

Based on Lazari Capital Management's 13F filing for Q4 2023, filed 27 Feb 2024.